NUMYTRIS
Live / Applied — Second extension granted (statement of use) (as of 01 Oct 2025)
What this means for you
Not registered yet, but its 13 Oct 2023 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98222595
- Mark type
- Stylized text
- Filed
- 13 Oct 2023
- Published for opposition
- 20 Aug 2024
- Attorney of record
- Carissa L. Weiss
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical products and preparations for the treatment of Prader-Willi syndrome (PWS) and related metabolic and neurodevelopmental disorders; pharmaceutical products and preparations for the treatment of neurodevelopmental and metabolic disorders
Owner
- Acadia Pharmaceuticals, Inc., San Diego, CA, US
- Acadia Pharmaceuticals, Inc., San Diego, CA, US
Prosecution history
- 02 Oct 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 01 Oct 2025 — SOU EXTENSION 2 GRANTED
- 01 Oct 2025 — SOU EXTENSION 2 FILED
- 01 Oct 2025 — SOU TEAS EXTENSION RECEIVED
- 29 Mar 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 28 Mar 2025 — SOU EXTENSION 1 GRANTED
- 28 Mar 2025 — SOU EXTENSION 1 FILED
- 28 Mar 2025 — SOU TEAS EXTENSION RECEIVED
- 15 Oct 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 20 Aug 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 20 Aug 2024 — PUBLISHED FOR OPPOSITION
- 31 Jul 2024 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 12 Jul 2024 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 12 Jul 2024 — EXAMINER'S AMENDMENT ENTERED
- 12 Jul 2024 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED